MA38454B1 - Inhibiteurs de protéines kinases - Google Patents

Inhibiteurs de protéines kinases

Info

Publication number
MA38454B1
MA38454B1 MA38454A MA38454A MA38454B1 MA 38454 B1 MA38454 B1 MA 38454B1 MA 38454 A MA38454 A MA 38454A MA 38454 A MA38454 A MA 38454A MA 38454 B1 MA38454 B1 MA 38454B1
Authority
MA
Morocco
Prior art keywords
protein kinase
kinase inhibitors
useful
formula
fgfr
Prior art date
Application number
MA38454A
Other languages
English (en)
Other versions
MA38454A1 (fr
Inventor
Srinivasan Rajagopalan
Prasad Appukuttan
Arumugam Karthikeyan Narasingapuram
Ravi Kotrabasaiah Ujjinamatada
Shyla George
Tero Linnanen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA38454A1 publication Critical patent/MA38454A1/fr
Publication of MA38454B1 publication Critical patent/MA38454B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i), dans laquelle r1 à r5, a, b, z, z1 et z2 étant tels que définis dans les revendications, et des sels pharmaceutiquement acceptables de celui-ci. Les composés de formule (i) selon l'invention sont utiles en tant qu'inhibiteurs de fgfr et sont utiles dans le traitement d'une affection où l'inhibition de la fgfr kinase est souhaitée, telle que le cancer.
MA38454A 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases MA38454B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN382KO2013 2013-04-04
PCT/FI2014/000003 WO2014162039A1 (fr) 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases

Publications (2)

Publication Number Publication Date
MA38454A1 MA38454A1 (fr) 2018-02-28
MA38454B1 true MA38454B1 (fr) 2018-11-30

Family

ID=50685938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38454A MA38454B1 (fr) 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases

Country Status (33)

Country Link
US (1) US20160031855A1 (fr)
EP (1) EP2981533B1 (fr)
JP (1) JP6356782B2 (fr)
KR (1) KR20150138383A (fr)
CN (1) CN105073733B (fr)
AR (1) AR095781A1 (fr)
AU (1) AU2014246961B2 (fr)
BR (1) BR112015025413A2 (fr)
CA (1) CA2907855A1 (fr)
CL (1) CL2015002932A1 (fr)
CY (1) CY1120306T1 (fr)
DK (1) DK2981533T3 (fr)
EA (1) EA031076B1 (fr)
ES (1) ES2658183T3 (fr)
HR (1) HRP20180382T1 (fr)
HU (1) HUE036692T2 (fr)
LT (1) LT2981533T (fr)
MA (1) MA38454B1 (fr)
MX (1) MX2015013776A (fr)
MY (1) MY184528A (fr)
NO (1) NO2981533T3 (fr)
NZ (1) NZ713410A (fr)
PE (1) PE20160115A1 (fr)
PH (1) PH12015502284A1 (fr)
PL (1) PL2981533T3 (fr)
PT (1) PT2981533T (fr)
RS (1) RS56942B1 (fr)
SA (1) SA515361260B1 (fr)
SG (1) SG11201508125XA (fr)
SI (1) SI2981533T1 (fr)
TW (1) TWI628176B (fr)
UA (1) UA115176C2 (fr)
WO (1) WO2014162039A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
CA3001969C (fr) 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Agent therapeutique destine au cancer du sein
US10487863B2 (en) * 2017-02-17 2019-11-26 Ford Global Technologies, Llc Castellated joint for improved adhesive coverage when using mechanical fixings and adhesive in one joint
WO2018166493A1 (fr) 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 Dérivé d'hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
EP3985005A4 (fr) * 2019-06-14 2023-07-19 CGeneTech (Suzhou, China) Co., Ltd. Composé cyclique fusionné en tant qu'inhibiteur double de fgfr et vegfr
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7300057B2 (ja) * 2019-07-26 2023-06-28 シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としてのピリジン誘導体
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021113462A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Dérivés d'un inhibiteur de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
AU2022213682C1 (en) * 2021-01-26 2025-04-17 Cgenetech (Suzhou, China) Co., Ltd Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method therefor
KR102655210B1 (ko) * 2021-03-26 2024-04-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503354A (ja) * 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
WO2001000207A1 (fr) * 1999-06-30 2001-01-04 Merck & Co., Inc. Composes inhibiteurs de la src kinase
WO2005021531A1 (fr) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble de benzimidazolyle c n substitue
US7977338B2 (en) * 2006-10-16 2011-07-12 Novartis Ag Phenylacetamides being FLT3 inhibitors
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
EP2114941B1 (fr) * 2006-12-22 2015-03-25 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
WO2011038579A1 (fr) * 2009-09-30 2011-04-07 Zhejiang Beta Pharma Inc. Composés et compositions comme inhibiteurs de protéines kinases
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази

Also Published As

Publication number Publication date
SA515361260B1 (ar) 2017-08-27
RS56942B1 (sr) 2018-05-31
MA38454A1 (fr) 2018-02-28
JP2016515604A (ja) 2016-05-30
EA201591913A1 (ru) 2016-03-31
MX2015013776A (es) 2016-02-26
PH12015502284B1 (en) 2016-02-01
UA115176C2 (uk) 2017-09-25
JP6356782B2 (ja) 2018-07-11
ES2658183T3 (es) 2018-03-08
CA2907855A1 (fr) 2014-10-09
HK1217198A1 (zh) 2016-12-30
AU2014246961B2 (en) 2017-09-28
MY184528A (en) 2021-04-01
LT2981533T (lt) 2018-02-26
HRP20180382T1 (hr) 2018-04-06
WO2014162039A1 (fr) 2014-10-09
CL2015002932A1 (es) 2016-04-22
US20160031855A1 (en) 2016-02-04
PT2981533T (pt) 2018-02-27
DK2981533T3 (en) 2018-02-12
SI2981533T1 (en) 2018-04-30
CY1120306T1 (el) 2019-07-10
NZ713410A (en) 2018-07-27
TW201524970A (zh) 2015-07-01
KR20150138383A (ko) 2015-12-09
EP2981533B1 (fr) 2017-12-06
TWI628176B (zh) 2018-07-01
AU2014246961A1 (en) 2015-10-22
HUE036692T2 (hu) 2018-07-30
AR095781A1 (es) 2015-11-11
SG11201508125XA (en) 2015-10-29
EA031076B1 (ru) 2018-11-30
CN105073733A (zh) 2015-11-18
EP2981533A1 (fr) 2016-02-10
PH12015502284A1 (en) 2016-02-01
PE20160115A1 (es) 2016-03-03
PL2981533T3 (pl) 2018-04-30
BR112015025413A2 (pt) 2017-07-18
CN105073733B (zh) 2017-06-27
NO2981533T3 (fr) 2018-05-05

Similar Documents

Publication Publication Date Title
MA38454A1 (fr) Inhibiteurs de protéines kinases
MA54327B1 (fr) Inhibiteurs de kras g12c
MA46337A (fr) Composé de pyridine
MA44820B1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
PH12020551464A1 (en) Cd73 inhibitors
MA52948B1 (fr) Composés
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA40225A (fr) Composés dihydroisoquinolinone substitués
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
MA39048A1 (fr) Nouveaux inhibiteurs de la dgat2
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA39983B1 (fr) Dérivés de carboxamide
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
BR112018010812A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
ZA202207449B (en) Selective cdk4/6 inhibitor cancer therapeutics
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam